Regulation of Striatal D1 Dopamine Receptor Density by D1 and D2 Antagonists

  • Sally J. Boyson
  • Paul McGonigle
  • Perry B. Molinoff
Part of the Satellite Symposia of the IUPHAR 10th International Congress of Pharmacology book series (SSNIC)


Elucidation of the respective functional roles of the D1 and D2 subtypes of dopamine receptors in the basal ganglia has been the subject of intense study in recent years. According to the definitions proposed by Kebabian and Calne (1979), D1 receptors stimulate adenylate cyclase, and D2 receptors either inhibit or have no effect on this enzyme. Until the last few years, no function was ascribed to the D1 receptor. Neuroleptics, drugs used to treat psychosis, are all antagonists at D2 receptors, although some are also antagonists at D1 receptors. Supersensitivity of D2 receptors has been proposed as the basis for tardive dyskinesia, a hyperkinetic involuntary movement disorder that may develop after long-term administration of neuroleptics. Dopamine agonists exacerbate tardive dyskinesia (Tarsy & Baldessarini, 1977) and administration of neuroleptics to rats results in an increase in the density of striatal D2 receptors (e.g., Burt et al., 1977).


Dopamine Receptor Tardive Dyskinesia Dopamine Antagonist Anterior Head Substantia Nigra Compacta 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Boyson, S.J., Flaim, K.E., and Molinoff, P.B. (1985). A new D-1 selective radioligand for autoradiography: SKF-83566. Soc. Neurosci. Abs., 11, 714.Google Scholar
  2. Boyson, S.J., McGonigle, P., Molinoff, P.B. (1986a). Quantitative autoradiographic localization of the D-1 and D-2 subtypes of dopamine receptors in rat brain. J. Neurosci., 6, 3177–3188.PubMedGoogle Scholar
  3. Boyson, S.J., McGonigle, P., Reuter, S., Schambron, D., and Molinoff, P.B. (1986b). Quantitative autoradiography of D-1 and D-2 dopamine receptors following administration of neuroleptics. Soc. Neurosci. Abs., 12, 192.Google Scholar
  4. Burt, D.R., Creese, I., and Snyder, S.H. (1977). Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science., 196. 326–328.CrossRefPubMedGoogle Scholar
  5. Calne, D.B. (1982). Dopamine receptors in movement disorders. In Movement Disorders, (eds. C.D. Marsden and S. Fahn). Butterworth Scientific, New York.Google Scholar
  6. Creese, I., and Chen, A. (1985). Selective D-1 dopamine receptor increase following chronic treatment with SCH-23390. Eur. J. Pharmacol., 109, 127–128.CrossRefPubMedGoogle Scholar
  7. Kebabian, J.W., and Calne, D.B. (1979). Multiple receptors for dopamine. Nature (Lond.), 277, 93–96.CrossRefGoogle Scholar
  8. Mailman, R.B., Schulz, D.W., Lewis, M.H., Staples, L., Rollema, H., and Dehaven, D.L. (1984). SCH-23390: a selective D1 dopamine antagonist with potent D2 behavioral actions. Eur. J. Pharmacol., 101, 159–160.CrossRefPubMedGoogle Scholar
  9. Meller, E., Kuga, S., Friedhoff, A.J., and Goldstein, M. (1985). Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist. Life. Sci., 36, 1857–1864.CrossRefPubMedGoogle Scholar
  10. Tarsy, D., and Baldessarini, R.J. (1977). The pathophysiologic basis of tardive dyskinesia. Biol. Psych., 12, 431–450.Google Scholar

Copyright information

© Sally J. Boyson, Paul McGonigle and Perry B. Molinoff 1988

Authors and Affiliations

  • Sally J. Boyson
    • 1
  • Paul McGonigle
    • 2
  • Perry B. Molinoff
    • 2
  1. 1.Departments of Neurology and PharmacologyUniversity of Colorado Health Sciences CenterDenverUSA
  2. 2.Department of PharmacologyUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations